NDAORALTABLET
Approved
Aug 2002
Lifecycle
Post-LOE
Competitive Pressure
35/100
Clinical Trials
20
Data completeness
5/8 — Partial
LEXAPRO (escitalopram) by AbbVie is escitalopram, the s-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (cns) resulting from its inhibition of cns neuronal reuptake of serotonin (5-ht). First approved in 2002.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lexapro (escitalopram) is an oral SSRI approved in 2002 for depression and anxiety disorders. It is the active S-enantiomer of citalopram that selectively inhibits serotonin reuptake in the central nervous system. The drug is a foundational treatment in psychiatry with well-established efficacy and tolerability.
$0.019BPart D
Post-LOEDeclining
Post-LOEPost-LOE positioning with significant generic erosion signals a mature, maintenance-focused team structure rather than growth-oriented staffing.
Mechanism of Action
escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
An Investigator-Initiated, Randomized, Double-Blind, Double-Dummy Study to Evaluate the Adjunctive Effect of CreNeuroS™ CNS Fish Oil Plus Softgels in Patients With Major Depressive Disorder Receiving Escitalopram.
Started Jun 2026
80 enrolled
Adjunct in the Treatment of Depressive Disorder
Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
Started May 2026
186 enrolled
Major Depressive DisorderMild Neurocognitive DisorderHIV
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
Started Mar 2021
132 enrolled
Anxiety
Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram
Started Oct 2020
0Major Depressive Disorder
A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Started May 2019
273 enrolled
Anxiety Disorders,Generalized Anxiety Disorder
Worked on LEXAPRO at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.